RxDoctor Payments Data

Rose Gonzalez

Physician Assistant · San Antonio, TXNPI 1013255397

Payments from drug & device makers

$6,605in general payments, 2019–2025

Across 371 payments — averaging $17.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$1K
  • AbbVie$925
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$716
  • Alkermes, Inc.$645
  • Johnson & Johnson$601
  • Lundbeck LLC$523
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$6,43197%
  • Education$1753%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,605 in reported general payments places this provider in the 90th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$8,293
Medicare patients
24
Services billed
90

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl16$21,996
Lurasidone Hcl28$11,487
Memantine Hcl56$1,497
Aripiprazole29$1,183
Hydroxyzine Hcl62$1,167
Venlafaxine Hcl ErVenlafaxine Hcl38$875
Mirtazapine60$762
Quetiapine Fumarate87$711
Donepezil Hcl91$695
Naltrexone Hcl16$630
Duloxetine Hcl29$576
Olanzapine39$481
Buspirone Hcl29$441
Trazodone Hcl60$421
Sertraline Hcl61$385

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$925$21,99616 claims
Almatica Pharma LLCSertraline Hcl$49$38561 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →